Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

820 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction.
Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Manzano-Fernández S, et al. Among authors: januzzi jl. Am J Cardiol. 2011 Jan 15;107(2):259-67. doi: 10.1016/j.amjcard.2010.09.011. Am J Cardiol. 2011. PMID: 21211603 Free PMC article. Clinical Trial.
Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure.
Manzano-Fernández S, Januzzi JL, Pastor-Pérez FJ, Bonaque-González JC, Boronat-Garcia M, Pascual-Figal DA, Montalban-Larrea S, Navarro-Peñalver M, Andreu-Cayuelas JM, Valdés M. Manzano-Fernández S, et al. Among authors: januzzi jl. Cardiology. 2012;122(3):158-66. doi: 10.1159/000338800. Epub 2012 Jul 24. Cardiology. 2012. PMID: 22832599
Short-term variability of heart rate turbulence in chronic heart failure.
Manzano-Fernández S, Pastor-Pérez FJ, Barquero-Pérez Ó, Pascual-Figal DA, Goya-Esteban R, Rojo-Álvarez JL, Caamaño-Fernández A, Martínez Martínez-Espejo MD, Januzzi JL, Valdés M, García-Alberola A. Manzano-Fernández S, et al. Among authors: januzzi jl. J Card Fail. 2011 Sep;17(9):735-41. doi: 10.1016/j.cardfail.2011.05.007. Epub 2011 Jun 23. J Card Fail. 2011. PMID: 21872143
Impact of kidney dysfunction on plasma and urinary N-terminal pro-B-type natriuretic peptide in patients with acute heart failure.
Manzano-Fernández S, Januzzi JL, Boronat-García M, Pastor P, Albaladejo-Otón MD, Garrido IP, Bayes-Genis A, Valdés M, Pascual-Figal DA. Manzano-Fernández S, et al. Among authors: januzzi jl. Congest Heart Fail. 2010 Sep-Oct;16(5):214-20. doi: 10.1111/j.1751-7133.2010.00153.x. Congest Heart Fail. 2010. PMID: 20887618 Free article.
Galectin-3 expression in cardiac remodeling after myocardial infarction.
Sanchez-Mas J, Lax A, Asensio-Lopez MC, Fernandez-Del Palacio MJ, Caballero L, Garrido IP, Pastor F, Januzzi JL, Pascual-Figal DA. Sanchez-Mas J, et al. Among authors: januzzi jl. Int J Cardiol. 2014;172(1):e98-e101. doi: 10.1016/j.ijcard.2013.12.129. Epub 2014 Jan 4. Int J Cardiol. 2014. PMID: 24433619 No abstract available.
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Maurer MS, et al. N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27. N Engl J Med. 2018. PMID: 30145929 Free article. Clinical Trial.
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
Verma S, Dhingra NK, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Peil B, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Reduced trial committees and investigators. Verma S, et al. Among authors: januzzi jl. Lancet Diabetes Endocrinol. 2022 Jan;10(1):35-45. doi: 10.1016/S2213-8587(21)00292-8. Epub 2021 Nov 30. Lancet Diabetes Endocrinol. 2022. PMID: 34861154
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Packer M, et al. N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28. N Engl J Med. 2020. PMID: 32865377 Clinical Trial.
820 results